Outcomes and toxicity in re-irradiation of gynecologic cancer: Systematic review of the Italian association of radiation and clinical oncology (AIRO).
Paola Critelli, Donato Pezzulla, Sara Lillo...
https://pubmed.ncbi.nlm.nih.gov/37913639/Actively Recruiting
Led by Affidea Nu-med Center of Oncological DIagnostics and Therapy · Updated on 2026-10-16
500
Participants Needed
1
Research Sites
261 weeks
Total Duration
Researchers are conducting an international, multicenter patient registry to observe adults with recurrent gynecologic cancers who have previously received radiotherapy and are treated or planned for reirradiation andor total ablative strategies. The study focuses on collecting data without assigning any treatments, aiming to understand real-world outcomes after these treatment approaches. The registry includes patients with various gynecologic malignancies such as uterine, cervical, vaginal, vulvar, ovarian, fallopian tube, primary peritoneal, and other rare types, who have recurrent or progressive disease and prior radiotherapy history. Participants receive treatments chosen by their local healthcare teams based on routine clinical care, which may include reirradiation modalities like brachytherapy, external-beam radiotherapy, stereotactic body radiotherapy, proton therapy, or intraoperative radiotherapy. Total ablative strategies may involve combinations of radiotherapy, surgery, ablation, systemic therapy, or other metastasis-directed therapies. The registry gathers both retrospective and prospective data, covering patients treated before or after the registry started, without altering or delaying any clinical decisions. During the study, data on patient demographics, tumor characteristics, prior treatments, recurrence details, treatment exposures, responses, progression, survival, adverse events including severe toxicities and fistula events, and patient-reported outcomes are collected. Outcomes like radiographic progression-free survival, overall survival, and treatment-related adverse events are monitored for up to five years. The registry captures a comprehensive dataset reflecting real-world clinical practice, with follow-up evaluations and quality-of-life assessments where available.
CONDITIONS
Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer
M
Mateusz Bilski, Md, PhD
P
Paulina Kleban, MGR
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Affidea Nu-med Center of Oncological DIagnostics and Therapy
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 10 years
Participants' treatment details, disease progression, and outcomes are collected from medical records and during follow-up visits without altering clinical care. Data includes prior radiotherapy, treatment exposures, responses, adverse events, and survival information.
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Paola Critelli, Donato Pezzulla, Sara Lillo...
https://pubmed.ncbi.nlm.nih.gov/37913639/Larissa J Lee, Gabriela M Alban, Teresa Cheng...
https://pubmed.ncbi.nlm.nih.gov/35078717/Sophie Bockel, Sophie Espenel, Roger Sun...
https://pubmed.ncbi.nlm.nih.gov/33799617/Diane C Ling, John A Vargo, Steven A Burton...
https://pubmed.ncbi.nlm.nih.gov/31150869/Diane C Ling, John A Vargo, Scott M Glaser...
https://pubmed.ncbi.nlm.nih.gov/30600093/Jaahid Mulani, Jeevanshu Jain, Ankita Gupta...
https://pubmed.ncbi.nlm.nih.gov/35537576/Nicolaus Andratschke, Jonas Willmann, Ane L Appelt...
https://pubmed.ncbi.nlm.nih.gov/36174633/Affidea Nu-med Center of Oncological DIagnostics and Therapy
Lead Sponsor